Functional status and right heart catheterisation at baseline, as well as 1 and 2 years after discontinuation of interferon-β and initiation of pulmonary arterial hypertension-specific therapy
| Baseline | 1 year | 2 years | |
| 6MWT m | 513 | 502 | |
| NYHA-FC | III | II | II |
| RAP mmHg | 5 | 6 | 3 |
| PAP syst/diast/mean mmHg | 74/42/53 | 49/21/30 | 41/20/27 |
| PAWP mmHg | 10 | 7 | 6 |
| CO L·min−1 | 3.3 | 6.5 | 6.3 |
| CI L·min−1·m−2 | 1.9 | 3.8 | 3.7 |
| PVR Wood units | 13 | 3.5 | 3.3 |
Vasoreactivity testing during the first right heart catheterisation with intravenous epoprostenol up to 12 ng·kg−1·min−1 was negative. 6MWT: 6-min walking test; NYHA-FC: New York Heart Association functional class; RAP: right atrial pressure; PAP: pulmonary artery pressure; syst: systolic; diast: diastolic; PAWP: pulmonary artery wedge pressure; CO: cardiac output; CI: cardiac index; PVR: pulmonary vascular resistance.